Financial Performance1Q EBITDA of $131M was ahead of consensus, with impressive revenue rising 25.9%, largely on strength across Pharmacy Solutions.
Market PositionBrightSpring trades at a slight premium compared to large-cap conglomerates but at a discount compared to the closest pure-play competitor, which suggests potential for value appreciation.
Specialty Pharmacy GrowthBrightSpring Health Services is expected to benefit from continued specialty growth and a generic wave driven by pharma's upcoming patent cliff.